SYNLAB UK & Ireland:

Modern Slavery & Human Trafficking Statement 2017

Published: 26th March 2017

Introduction

SYNLAB Group is committed to the UK Government’s objectives of eradicating modern slavery and human trafficking.  SYNLAB Group is committed to ensuring that the supply chains of its subsidiaries and their business activities are free from ethical and labour standards abuse.

 

The Organisational Structure

SYNLAB Group are market leaders in Europe for medical diagnostic services for practising doctors (GPs), individual patients, clinics, hospitals and the pharmaceutical industry.

SYNLAB Limited (“SL”) is the ultimate parent company of all the subsidiaries that belong to the SYNLAB group of companies (“SYNLAB Group”). SL provides head office support activities to its subsidiaries by way of providing guidelines, advice and assistance.

In the UK, the SYNLAB Group operates through Labco UK Group Limited (“LUKGL”).

LUKGL is the main operating group of businesses, ultimately owned by SL, which delivers high quality pathology testing and imaging services.

The rest of this statement will focus solely on SL’s steps in complying with Modern Slavery Act 2015.

SYNLAB Limited’s Compliance to the Modern Slavery Act 2015

SL supports all its subsidiaries in ensuring that there is full compliance with local labour and employment legislation. SL provides quarterly reporting on relevant HR, Social and Environmental related performance indicators to the SYNLAB Group’s Head of HR and Organisation and to the Board of Directors. SL drives the local management of its subsidiaries, including LUKGL, to ensure that specific supply chain policies are adopted, which have, as one of their main objectives, supplier due diligence for both new and existing suppliers.

SL has also supported its subsidiaries to continuously improve their systems and procedures to detect potential modern slavery and human trafficking risks arising around particular products and geographical areas.

SL will procure that its subsidiaries will conduct an overall review of the SYNLAB Group’s existing supply chains in various countries, including the UK, in order to harmonize local sourcing practices in accordance with SL’s guidelines and specific tasks, and relevant performance indicators will be introduced. These measures will embed verifications and checks into the supply chain, ensure early detection of potential critical situations and enforce actions to reduce, mitigate and eliminate any modern slavery and human trafficking risks, as well as preserve and improve SYNLAB’s reputation on the global market.

SL will ensure that its subsidiaries raise awareness of modern slavery and human trafficking issues among the wider workforce at all SYNLAB locations and operations globally. SL will work through its subsidiaries’ HR and the organisation is committed to ensuring that appropriate training and awareness initiatives are put in place to meet this goal.

SL will review its actions in relation to the above annually.

This statement is made pursuant to Section 54(1) of the Modern Slavery Act 2015 and constitutes SL’s Modern Slavery & Human Trafficking Statement for the financial year 2016/2017.

This statement has been approved and authorised by the SYNLAB Limited board of directors.

Latest SYNLAB UK & Ireland News
SYNLAB sets its Sights on Becoming the UK’s Leading Laboratory Diagnostics Organisation

Published: 23rd August 2023Science for Life, Health and Wellbeing SYNLAB, the medical diagnostics provider, has set out its ambition to become the UK’s leading  laboratory…

Read More (about 'SYNLAB sets its Sights on Becoming the UK’s Leading Laboratory Diagnostics Organisation')
Modern Slavery & Human Trafficking Statement 2023

Published: 11th July 2023INTRODUCTION This is SYNLAB UK and Ireland’s (SYNLAB UK&I) Modern Slavery and Human Trafficking Statement under Section 54 of the UK Modern…

Read More (about 'Modern Slavery & Human Trafficking Statement 2023')
Exceptional talent honoured during SYNLAB awards programme

Published: 8th December 2022SYNLAB’s 2022 Excellence Awards recognised individuals and teams from across its UK & Ireland services, who display outstanding service in their roles….

Read More (about 'Exceptional talent honoured during SYNLAB awards programme')
SYNLAB Primed to Help Steer NHS’s COVID Bounce Back

Published: 13th October 2022SYNLAB is ready to play a key role in assisting the UK’s ongoing COVID recovery after securing membership of NHS England’s Increasing…

Read More (about 'SYNLAB Primed to Help Steer NHS’s COVID Bounce Back')
Landmark Day for Pathology Partnership with Launch of Synnovis Brand

Published: 4th October 2022 A pathology partnership performing 32 million tests a year has been relaunched as ‘Synnovis’ – officially heralding the start of a…

Read More (about 'Landmark Day for Pathology Partnership with Launch of Synnovis Brand')
Pathology laboratory becomes the first in the UK to support remote plate reading  

Published: 15th June 2022A pathology laboratory is leading the way in speeding up access to patient care and treatment after becoming the first in the…

Read More (about 'Pathology laboratory becomes the first in the UK to support remote plate reading  ')
SYNLAB ESG Roadmap and Framework

Published: 17th May 2022Introduction SYNLAB UK&I is thrilled to publish its UK&I ESG Framework and Roadmap, which outlines out how we will achieve our ESG…

Read More (about 'SYNLAB ESG Roadmap and Framework')
GENDER Pay Gap Report 2020-21

Published: 21st September 2021A Message From Our CEO Whilst we are pleased at the improvement in our gender pay gap over the past four years,…

Read More (about 'GENDER Pay Gap Report 2020-21')